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CXCR4It is widely documented that a complete switch from the predominant CCR5 (R5) to CXCR4 (X4) phenotype
is less common for HIV-1 subtype C (HIV-1C) compared to other major subtypes. We investigated whether
dualtropic HIV-1C isolates represented dualtropic, mixed R5 and X4 clones or both. Thirty of 35 functional
HIV-1 env clones generated by bulk PCR ampliﬁcation from peripheral blood mononuclear cells (PBMCs)
infected with seven dualtropic HIV-1C isolates utilized CXCR4 exclusively. Five of 35 clones displayed
dualtropism. Endpoint dilution of one isolate did not yield a substantial proportion of R5-monotropic env
clones. Sequence-based predictive algorithms showed that env sequences from PBMCs, CXCR4 or CCR5-
expressing cell lines were indistinguishable and all possessed X4/dualtropic characteristics. We describe
HIV-1C CXCR4-tropic env sequence features. Our results suggest a dramatic loss of CCR5 monotropism as
dualtropism emerges in HIV-1C which has important implications for the use of coreceptor antagonists in
therapeutic strategies for this subtype.
© 2009 Elsevier Inc. All rights reserved.Introduction
HIV/AIDS is the most serious infectious disease challenging the
public health sector in sub-Saharan Africa. The disease remains the
leading cause of death in the region and in 2007 alone, 76% of deaths
were as a result of HIV/AIDS, with 68% of all new HIV infections
occurring in this region. Southern Africa is the most seriously affected
sub-region and in 2007 accounted for 32% of all new infections and
AIDS-related deaths worldwide. South Africa constitutes the highest
number of HIV infections globally (UNAIDS, 2007). The main
circulating HIV-1 subtype in South Africa is HIV-1 subtype C (HIV-
1C), which accounts for approximately 56% of infections worldwide
(Esparza, 2005; Hemelaar et al., 2006; Visawapoka et al., 2006).
Subtype groupings are based on sequence variations that occur within
all gene and non-protein coding regulatory regions, but the most
dramatic differences are found in the envelope (env) gene (Gao et al.,
1998). The envelope is an important target of humoral immune
responses and is a crucial determinant of overall viral ﬁtness (Ball et
al., 2003; Marozsan et al., 2005). The env gene plays an important rolearch Institute, University of
South Africa. Fax: +2731 260
l rights reserved.in viral transmission by determining which coreceptor the virus uses
to mediate entry. During transmission and subsequent to infection,
viral ﬁtness and target cell tropism properties are thought to be
important determinants of infectivity and the rate of disease
progression (Troyer et al., 2005). The importance of the envelope as
a major target of humoral immunity, its contribution to overall ﬁtness
during transmission, and its role in the rate of disease progression
make it a particularly attractive target for vaccine and drug
development. However, progress towards these goals has been
greatly hindered by the extreme genetic variability of the env gene.
HIV-1 utilize members of the seven transmembrane chemokine
receptor family as coreceptors for entry into target cells (de Roda
Husman et al., 1999; Oppermann, 2004; Ross and Cullen, 1998; Vila-
Coro et al., 2000; Xiao et al., 1999). The virus gp120 envelope
glycoprotein ﬁrst binds to the primary CD4 receptor on target cells,
which induces conformational changes on the envelope exposing the
coreceptor binding site (Rizzuto et al., 1998; Wyatt et al., 1995). The
two main coreceptors that the HIV-1 envelope binds to subsequent to
the conformational change are CCR5 or CXCR4 (Alkhatib et al., 1996;
Choe et al., 1996; Deng and Liu, 1996; Doranz et al., 1996; Dragic and
Litwen, 1996; Feng and Broder, 1996). HIV-1 strains can be classiﬁed
based on their coreceptor utilization, with CCR5 tropic viruses termed
R5, CXCR4 tropic viruses termed X4 and viruses that use both
coreceptors (dualtropic viruses) termed R5X4 (Berger, 1998; Berger,
Murphy, and Farber, 1999). R5 viruses predominate in the early stages
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associated with rapid disease progression, emerge in the late chronic
phase of disease in a signiﬁcant proportion of patients (Connor et al.,
1997; Scarlatti et al., 1997). It is well established that while all
subtypes are capable of undergoing coreceptor utilization switch
from CCR5 to CXCR4, this is less frequently encountered in HIV-1
subtype C infections, even in late stages of disease (Bjorndal and
Sonnerborg, 1999; Cecilia et al., 2000; Cilliers et al., 2003; Ndung'u
et al., 2006; Tscherning et al., 1998). Furthermore, expanded
coreceptor usage beyond CCR5 and CXCR4 has also been occasion-
ally reported but its signiﬁcance for HIV-1 replication in vivo and
disease progression is unclear (Aasa-Chapman et al., 2006; Cilliers
et al., 2005; Dash et al., 2008).
Coreceptor utilization is genetically determined by sequence
characteristics within the env gene, primarily speciﬁc amino acid
changes within three of the ﬁve hypervariable regions namely the V1/
V2 and V3 loops, as well as the number and pattern of predicted N-
linked glycosylation sites (Fouchier et al., 1992; Pastore and Nedellec,
2006; Pollakis et al., 2001). Additional sequence changes within the
env gene have also been implicated in coreceptor determination or
the coreceptor switching process (Aasa-Chapman et al., 2006; Coetzer
et al., 2008).
In several instances where HIV-1 subtype C isolates able to
mediate cell entry via CXCR4 have been described, dualtropic (R5X4)
strains that utilize both CCR5 and CXCR4 have been more frequently
encountered compared to X4 monotropic viruses (Cilliers et al., 2003;
Coetzer et al., 2006; Dash et al., 2008; Johnston et al., 2003; Ndung'u et
al., 2006; van Rensburg et al., 2002). However, despite the occasional
isolation of dualtropic HIV-1C viruses, such viruses have rarely been
extensively characterized at both the functional and genetic clonal
level. It is therefore largely unknown whether dualtropic HIV-1C
strains represent a mixture of R5 and X4 viruses or truly dualtropic
strains (or both) at the clonal level. Furthermore, genetic determi-
nants associated with change in coreceptor usage have rarely been
described for HIV-1 subtype C, particularly those that may reside
outside of the V3 loop region. In this study we investigated whether
dualtropic HIV-1C primary isolates represented truly dualtropic
viruses at the clonal level, or mixed R5 and X4 clones. We describe
the generation of functional envelope clones from dualtropic HIV-1C
isolates and the sequence characteristics in the HIV-1C env gene, both
within and outside of the V3 region that are associated with
coreceptor utilization phenotype.Fig. 1. Viral infection of PBMCs. 5000 pg p24 antigen equivalent of virus was used to infect s
over a 14-day period. BWM01_5 is an R5 monotropic viral isolate and was used as a positiv
(BW17, TM1B, RP1, SW20, SW30, Du36_5, CM9 and BWMO1_5).Results
Viral infection of stimulated PBMCs
Seven HIV-1 subtype C dualtropic isolates from individuals in
South Africa (Cilliers et al., 2003) and Botswana (Ndung'u et al., 2006)
were selected for this study. In addition, a well-characterized CCR5-
only utilizing HIV-1 subtype C isolate, BWM01_5 was used as a
positive control (Ndung'u et al., 2006). Infection of the stimulated
PBMCswas assessed by HIV-1 p24 antigen ELISA over a 14-day culture
period. As shown in Fig. 1, p24 antigen concentration increased in
culture supernatant for all the isolates. The isolates replicated to
different levels and with different replication kinetics. On day 14,
culture supernatants were removed and genomic DNA was extracted
from the cells for env gene ampliﬁcation.
Conﬁrmation of dualtropism of primary viral isolates
We ﬁrst analyzed the seven primary viral isolates propagated in
PBMCs for their ability to use multiple coreceptors on cell lines.
Speciﬁcally, we analyzed for ability to mediate cell entry via CCR5 or
CXCR4 because these are the main coreceptors previously described
for a signiﬁcant proportion of HIV-1 primary isolates. In order to
assess the ability of the isolates to utilize these coreceptors, virus
equivalent to 2 ng of p24 antigen each was used to infect U87.CD4
glioma cell lines with or without the co-expression of the coreceptors.
Table 1 shows the highest amounts of p24 antigen reached by the
primary isolates over a 10-day period in culture. All 7 primary viral
isolates replicated in cells expressing CXCR4 and CCR5. It was
noteworthy that while all the isolates replicated efﬁciently in CXCR4
expressing cells, 3 isolates (RP1, SW30 and CM9) replicated to
relatively low titers in cells expressing CCR5. Isolates CM9 and SW30
were previously shown to replicate efﬁciently in both CCR5 and
CXCR4 expressing cell lines (Cilliers et al., 2003) and therefore our
results could indicate that in vitro passages of the isolates is selecting
against CCR5 utilization.
Determination of coreceptor usage by env clones
The env gene (approximately 3 kb) was then ampliﬁed from
PBMC genomic DNA by PCR, gel puriﬁed and cloned into a
mammalian cell expression plasmid vector (pcDNA3.1D/V5-His-timulated PBMCs. Virus growth was monitored by p24 antigen concentration increased
e control. All isolates and clones are referred to by their shorter names within the text
Table 1
Coreceptor usage characterization of primary viral isolates.
Isolate CD4 count
(cells/μl)
Viral load
(copies/ml)
Highest p24 antigen (pg/ml) reached by
primary isolates over 10-day period in culture
U87.CD4 U87.CD4.CCR5 U87.CD4.CXCR4
96BW17 NA NA (19) 630 (25) 707,297 (10) 209,119
99ZATM1B NA 190,000 (13) 610 (151) 32,012 (126) 98,654
RP1 7 178,830 (0.9) 610 (1.2) 2120 (646) 961,835
99ZASW20 2 43,595 (0.2) 0 (0.2) 160,683 (1.5) 47,787
99ZASW30 2 73,860 (0.8) 1 (0.8) 2141 (1.0) 158,623
99ZACM9 24 NA (1.1) 2 (1.2) 2201 (1.1) 11,979
01ZADu36_5 25 54,944 (1.3) 1 (2.1) 1,658,728 (1.0) 46,525
96BWM01_5 NA NA – – –
Du179 279 2640 – – –
NA—not available. All patients were ART naive.
2000 pg of p24 viral supernatants from PBMC co-cultures was used to infect U87.CD4
cells expressing different coreceptors i.e. CCR5 or CXCR4 coreceptors. The U87.CD4 cell
line was used as a control cell line. We used 2000 pg of HIV-1 p24 equivalent of virus to
infect and cells were washed 3 times after overnight incubation with infecting stock.
Virus growth above 2000 pg (amount used to infect) was considered productive
infection of target cells. All italicized ﬁgures in brackets indicate background level i.e.
the p24 antigen (pg/ml) on day 0.
Table 2
Coreceptor usage characterization of the HIV-1C env clones.
Clone U87.CD4.CCR5 U87.CD4.CXCR4 Accession number
96BW17 #2 − +++ FJ846633
96BW17 #3 − +++ FJ846634
96BW17 #6 − +++ FJ846635
96BW17 #7 − +++ FJ846636
96BW17 #15 − +++ FJ846637
99ZATM1B #3 − +++ FJ846653
99ZATM1B #5 − +++ FJ846654
99ZATM1B #6 − ++ FJ846655
99ZATM1B #8 − ++ FJ846656
99ZATM1B #13 − ++ FJ846657
RP1 #5 − ++ FJ846658
RP1 #6 − ++ FJ846659
RP1 #8 − ++ FJ846660
RP1 #10 ++ ++ FJ846661
RP1 #13 ++ ++ FJ846662
99ZASW20 #2 − ++ FJ846643
99ZASW20 #3 − ++ FJ846644
99ZASW20 #11 − ++ FJ846645
99ZASW20 #14 − +++ FJ846646
99ZASW20 #15 − ++ FJ846647
99ZASW30 #1 − ++ FJ846648
99ZASW30 #2 − +++ FJ846649
99ZASW30 #3 − +++ FJ846650
99ZASW30 #6 − +++ FJ846651
99ZASW30 #9 − +++ FJ846652
01ZADu36_5 #2 − +++ FJ846628
01ZADu36_5 #7 − +++ FJ846629
01ZADu36_5 #8 − ++ FJ846630
01ZADu36_5 #9 − +++ FJ846631
01ZADu36_5 #10 − ++ FJ846632
99ZACM9 #1 ++ +++ FJ846638
99ZACM9 #2 ++ +++ FJ846639
99ZACM9 #16 − +++ FJ846640
99ZACM9 #18 − +++ FJ846641
99ZACM9 #21 + +++ FJ846642
96BWM01_5a +++ −
96BW17#10a − +++
Du179a +++ +++
pNL4-3.Luc.R-E-a − −
For each experiment, a positive result was considered to be 2 × the average relative
luminescenceunits (RLUs)of thenegative controlwells+standarddeviation. RLUsabove
this but less than 3× this cutoff value are indicatedby “+”, values 3× to10×above cut off
are shown as “++” and values above 10 × the cut off are indicated as “+++”.
a 96BWM01_5 is an R5-only control, 96BW17#10 is an X4-only control and Du179 is
an R5X4 contol. pNL4-3.Luc.R-E- is the negative control.
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Pseudoviruses were prepared by cotransfecting 293T cells with
each of the 35 env plasmid clones with the pNL4-3.Luc.R-E-
construct (Connor et al., 1995; He et al., 1995). This construct
contains the infectious NL4-3 provirus backbone but is env and vpr
deleted and nef has been replaced by the ﬁreﬂy luciferase gene.
Virus supernatant from the transfected 293T cells equivalent to 2 ng
p24 antigen was then used to infect U87 cells expressing the
chemokine receptors CCR5 or CXCR4. A previously characterized
dualtropic env clone Du179 (Coetzer et al., 2006) was used in
parallel as a positive control. Productive entry of target cells was
determined by measurement of ﬁreﬂy luciferase activity in cell
lysates of infected U87 cells. All 35 env clones were able to
efﬁciently infect cells expressing CXCR4 (Table 2). Five of 35 (14.3%)
clones tested were also able to mediate entry via the CCR5 receptor,
indicating that they were dualtropic. Two of the clones able to
utilize CCR5 were from isolate RP1 while the other three were from
isolate CM9. Surprisingly, there were no CCR5 monotropic clones
detected from the bulk PCR envelope analysis of dualtropic isolates
in this study.
We then reasoned that there were two possibilities to explain
these results; one is that CCR5 monotropic envelopes are present at
very low frequencies and therefore are virtually undetectable as
clones from amongst the primary isolate viral quasispecies or that the
CXCR4 viruses may be more ﬁt and outcompeting CCR5 clones when
propagated in PBMCs. In order to differentiate between these two
possibilities, we infected U87.CD4.CCR5 cells with each of the primary
viral isolates, with the objective of amplifying or favoring the CCR5-
tropic clones in CCR5-only expressing cells. RNA was then extracted
from the viral supernatant from U87.CD4.CCR5 cells, functional env
clones generated and coreceptor usage determined as described for
the PBMC-derived clones. All clones generated from U87.CD4.CCR5
cell supernatants showed dualtropism (data not shown). This result
suggests that env clones using CCR5 only were virtually absent or
present at very low frequencies within the quasispecies of the 7
primary isolates analyzed here.
Limiting endpoint dilution PCR
We also considered the possibility that bulk PCR env ampliﬁcation
and cloning could result in resampling bias and explain the absence of
CCR5-only env clones. We thus used a single genome ampliﬁcation
approach to generate diverse clones from isolateDu36_5. This clonewas
selected for this analysis because it showed a bias towards CCR5utilization and yet we had failed to identify CCR5-only tropic clones
from this isolate. Thirty clones of DU36_5were ampliﬁed and cloned by
this limiting endpoint dilution PCR approach. These clones were then
tested for coreceptor usage in the U87.CD4.CCR5 and U87.CD4.CXCR4
cell lines. Of the 26 functional clones, 24were dualtropic, one clone used
CXCR4 exclusively and one clone showed exclusive R5-usage.
Genotypic analysis of the env gene
All 35 env full-length clones generated in this study by bulk PCR
were sequenced to investigate phylogenetic relationships and to
correlate coreceptor usage phenotype to genotype data. Phyloge-
netic analysis showed that all clones clustered with subtype C
references with a high degree of conﬁdence (Fig. 2). Furthermore,
the clones from each primary viral isolate clustered together. As
described above, sequences were also generated from U87.CD4.
CCR5 and U87.CD4.CXCR4 cells infected with each of the primary
isolates. These clones utilized both CCR5 and CXCR4, and their
sequences were virtually phylogenetically indistinguishable from
those obtained from PBMC cultures. Results obtained by using
position-speciﬁc scoring matrix for HIV-1 subtype C (C-PSSM), a
phenotype predictive tool based on HIV-1 subtype C sequences
(Jensen et al., 2006) indicated CXCR4 or dualtropic phenotype and
high net V3 charges (data not shown).
Fig. 2.Neighbour-Joining phylogenetic tree constructed from the env gene sequences. All clones of a particular viral isolate cluster closely together. Furthermore, all clones cluster with the subtype C reference with a high degree of conﬁdence.
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Fig. 3. Alignment of V3 sequences of clones of primary viral isolates. The crown motif for each sequence is indicated in blue and dualtropic clone sequences are indicated in green.
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Table 3
Summary table of V3 characteristics of clones of primary viral isolates.
Clone A.A length Calc V3 net charge PSSM V3 net charge Amino acid (11/25) Crown motif PSSM coreceptor usage Phenotype prediction
R-5 only virus 96BWM01_5 35 4 4 Ser (S)/Asp (D) GPGQ CCR5-using only CCR5-using
96BW17 #2; 3; 6; 7; 15 37 7 7 Ser (S)/Arg(R) GRGQ CXCR4-using CXCR4-using or dt
99ZATM1B #3; 5; 6; 8; 13 37 8 8 Asp(N)/Arg(R) GRGQ CXCR4-using CXCR4-using or dt
P1 #5; 6; 8; 10; 13 37 8 8 Arg(R)/Arg(R) GPGQ CXCR4-using CXCR4-using or dt
99ZASW20; #2; 3; 11; 14; 15 37 6 6 Ser(S)/Glut(Q) GRGQ CXCR4-using CXCR4-using or dt
99ZASW30 #1; 2; 3; 6; 9 37 9 8 Ser(S)/Lys(K) GRGH CXCR4-using CXCR4-using or dt
01ZADu36_5 #2; 9 36 8 8 Arg(R)/Gly(G) GPGR CXCR4-using CXCR4-using or dt
01ZADu36_5 #7; 8; 10 36 7 7 Arg(R)/Gly(G) GPGR CXCR4-using CXCR4-using or dt
99ZACM9 #1; 2; 16; 18; 21 35 6 6 Thr(T)/Arg(R) GPRY CXCR4-using CXCR4-using or dt
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utilization (Briggs et al., 2000; Cann et al., 1992; Fouchier et al., 1992;
Rizzuto et al., 1998; Wu et al., 2006). Therefore, we further analyzed
the V3 loop of the functionally characterized env clones in order to
identify and describe sequences associated with dualtropism and
CXCR4 utilization (Fig. 3 and Table 3). Of particular interest was the
crownmotif, a conserved tetrapeptide located at the tip of the V3 loop.
Changes within this region may inﬂuence coreceptor usage. The
consensus crown motif for clones from isolate RP1 was GPGQ, which
is the conventional V3 loop crown sequence observed in CCR5-tropic
subtype C sequences. The crown motifs for clones generated from
Du36_5 and CM9 were GPGR and GPRY respectively, sequence
substitutions that are indicative of CXCR4 tropism (Coetzer et al.,
2006). Clones from BW17, TM1B and SW20 each displayed consensus
crown motif sequences that read GRGQ. The consensus crown motifs
of SW30, Du36_5 and CM9 read GRGH, GPGR and GPRY respectively.
Thus CXCR4 utilization in HIV-1 subtype C is commonly associated
with a basic amino acid substitution in the V3 tetrapeptide although
this is not an absolute requirement.
Another feature of the env V3 loop associated with tropism
determination is the property of amino acids at positions 11 and/or
25 (Fouchier et al., 1992). The consensus sequences for all isolates
with the exception of SW20 showed a positively charged amino acid
substitution at one or both of these positions. BW17 has serine (S)
(neutral charge) and arginine (R) (positively charged); TM1B has
asparagine (N) (neutral) and arginine, SW20 has serine and
glutamine (Q) both of which carry neutral charges, SW30 has serine
and lysine (K), Du36_5 has arginine and glycine (G) and CM9 has
arginine and threonine (T) at positions 11 and 25 respectively. RP1
has arginine at both positions. The number of amino acids in the V3
loop can also be indicative of coreceptor usage. The typical V3 loop
from CCR5 tropic viruses has 35 amino acids. Clones from CM9 were
35 amino acids long in the V3 loop, whereas clones from Du36_5
were 36 amino acids long. Clones from isolates TM1B, SW30 and
BW17 had 2-amino acid insertions, increasing the length of the V3
loop to 37 amino acids. The insertions occurred at positions 13 and
14 of the V3 loop for clones from isolates RP1 and SW20 and at
positions 6 and 7 for clones from Du36_5. Clones from TM1B, SW30
and BW17 had insertions between positions 15 and 16. Amino acid
insertions in the V3 loop, particularly at positions 13 and 14 are
features consistent with CXCR4 utilization as previously described
(Coetzer et al., 2006). None of the insertions observed in the V3 loop
of the clones from this study was noted in HIV-1 subtype C R5
sequences downloaded from the Los Alamos database (www.hiv.lanl.
gov) (data not shown). The V3 region was also analyzed by manually
calculating the overall net amino acid charge, another indicator of
env coreceptor tropism (Table 3). C-PSSM, a web-based bioinformatic
tool used for predicting HIV-1C coreceptor usage from the amino acid
sequences of the V3 loop (Jensen et al., 2006) was also used. Both
manual and C-PSSM calculations were comparable except for the
clones from SW30 where calculated scores were slightly higher than
C-PSSM generated scores. Higher overall net V3 charges are
associated with X4-usage. A charge less than +4.5 is regarded asR5-using and charges above +4.5 are regarded as X4-using (Coetzer
et al., 2006; Fouchier et al., 1995; Fouchier et al., 1992; Kuiken et al.,
1992). Therefore, based on the multiple V3 loop sequence based
algorithms available for phenotype prediction, all clones generated in
this study were either only CXCR4-using or dualtropic, consistent
with the functional data.
We next analyzed the V1/V2 and V4/V5 regions of the env gene as
these regions have also been implicated in playing a role in viral
tropism. Sequence features in these regions that may inﬂuence
coreceptor utilization are the amino acid length and the number of
predicted N-linked glycosylation sites (Chohan et al., 2005; Coetzer et
al., 2007; Coetzer et al., 2008; Masciotra et al., 2002; Pollakis et al.,
2001). The number of predicted N-linked glycosylation sites in clones
from this study varied from 23 to 33. Clones for RP1, SW20 and SW30
all had 30 predicted N-linked glycosylation sites. Within the V1/V2
and V3 regions, the N-linked glycosylation sites varied between
isolates but occurred at the same positions for all clones of the same
isolate irrespective of whether they were X4-using or dualtropic
except for one clone from TM1B which had 2 predicted N-linked
glycosylation sites in the V2 region whereas the other 4 clones of this
isolate had 3. The sites within the V4/V5 regions for all clones of all
isolates showed slight variations in position. However, all clones from
Du36_5 exhibited CXCR4-usage and showed variation in the positions
of the sites in all ﬁve hypervariable regions. The positions of N-linked
glycosylation sites varied from clone to clone and based on these
positions no pattern emerged that could distinguish CXCR4-using
clones from those that used both CCR5 and CXCR4.
When the total number of predicted N-linked glycosylation sites
within the env as well as within the V1/V2 and V4/V5 regions was
analyzed, no signiﬁcant difference was observed between the CXCR4-
using clones and dualtropic clones. However, the median number of
N-linked glycosylation sites for X4/X4R5 clones from this study was
signiﬁcantly higher at (30) compared to (21) for R5 clones (30
sequences downloaded from the Los Alamos HIV-1 database)
(p b0.0001) (Figs. 4A–C). R5 sequences showed a lower number of
predicted N-linked glycosylation sites within the entire env as well as
within the V1/V2 and V4/V5 regions when compared to R5X4/X4
clonal sequences.
Previous reports have suggested that a lack of predicted N-linked
glycosylation sites at positions 6–8 of the V3 loop may be indicative of
CXCR4-usage (Coetzer et al., 2006).We found this site to be conserved
in the clones analyzed in this study, despite the utilization of CXCR4
by all the clones. All clones (except those from isolate Du36_5)
contained a predicted N-linked glycosylation site at position 6
although they were CXCR4-using. This was also observed in a
previous study by Johnston et al. (2003) where all but one X4
sequence maintained this site. We found a signiﬁcant reduction in the
number of predicted N-linked glycosylation sites within the V3 region
of clones generated in this study as compared to the R5 sequences
from the database (Fig. 4D).
The entire env sequence i.e. gp160 of all CXCR4- and CCR5/CXCR4-
using clones were compared to determine if any distinguishing
features could be identiﬁed. Speciﬁcally, we analyzed for unique
Fig. 4. Box plots of putative N-linked glycosylation sites (PNLGS) and env variable loop lengths. (A) Shows the total number of PNLGSwithin the env. (B) The number of PNGLS within
the V1/V2 region. (C) The number of PNGLS within the V4/V5 region. (D) The number of PNLGS within the V3 region. (E) The V1/V2 loop length. (F) The V4/V5 loop length. (G) The
V3 loop length. The line within each box represents the median value for each group. ⁎Indicates R5 sequences downloaded from the Los Alamos database (www.hiv.lanl.gov).
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charge or physical property at a particular position, putative N-linked
glycosylation sites, deletions, insertions or number of amino acids.
The 2 clones of RP1 displaying dualtropism (i.e. clones #10 and 13)
had leucine (L) at position 373 whereas the CXCR4-using clones of
this isolate (clones #5; 6; 8) had proline (P) at this position (data not
shown). The other isolate that produced clones exhibiting dualtrop-
ism was CM9. No distinguishing signature sequences were noted that
could differentiate between X4 and X4R5 sequences.
We next analyzed for differences in the loop lengths between X4,
X4R5 and R5 sequences. Most variation was seen in V1 which ranged
from 16 to 27 amino acids. V2 had a relatively constant loop length
(40–45). The combined V4/V5 loop length ranged from 37 to 46. The
V1/V2 and V4/V5 loop lengths of the clones produced in this study
were plotted against R5 sequences from the Los Alamos database. No
signiﬁcant differences were observed between the V1/V2 sequences
of clones generated in this study and the R5 sequences from the Los
Alamos database (Fig. 4E). However, for the V4/V5 region, there was a
signiﬁcant difference between the generated clones using the CXCR4
coreceptor for viral entry and the dualtropic clones (p=0.015) (Fig.
4F), with the dualtropic clones having an increased V4/V5 loop length.
For the V3 loop, all analyzed R5 sequences had a loop length of 36
amino acids whereas X4 and R5X4 clones from this study showed
variability with a range from 35 to 37 amino acids (Fig. 4G).
Discussion
The requirement by HIV-1 for speciﬁc cellular interacting factors
during the entry step offers an opportunity for the development of
vaccines and drugs that target this crucial step in the virus
replication cycle (Dhami et al., 2009; Hunt and Romanelli, 2009;
Pantophlet and Burton, 2006; Phogat et al., 2007). Coreceptors play
an important role in initiating infection at the cellular level.
Additionally, coreceptor utilization is an important determinant of
the rate of disease progression. The emerging availability of entry
inhibitors such as the CCR5 antagonists underlines the importance
of better characterization of coreceptor utilization and cellular
tropism by HIV-1 isolates particularly in heavily burdened countries
where the drugs are likely to be required on a large scale for the
clinical management of HIV/AIDS. In this study, we generated 35
full-length env clones from seven dualtropic isolates of HIV-1
subtype C, in order to determine whether they were a mixture of
CCR5 and CXCR4 quasispecies or dualtropic viruses at the clonal
level. We also interrogated the sequence characteristics of these
clones in order to better elucidate the genetic determinants of
coreceptor utilization by HIV-1 subtype C viruses. We found that
CXCR4-tropic clones dominated within the dualtropic viral isolates
quasispecies. A minority proportion of dualtropic clones were also
identiﬁed. Unexpectedly, we found that there was not a single
CCR5-monotropic env clone from the seven primary isolates
analyzed in this study. This is an unusual ﬁnding considering that
many studies have shown that HIV-1 subtype C viruses even in late
stages of disease utilize CCR5-only predominantly for cell entry. We
thus expected to ﬁnd a signiﬁcant proportion of the remnants of
these viruses among the quasispecies of the dualtropic isolates.
Instead, all the clones detected in this study used CXCR4 as the
coreceptor for cell entry, with a minority of these (14.3%) also able
to mediate entry via the CCR5 receptor. Our results may explain
why in previous studies of some of the dualtropic isolates described
here (CM9, SW20 and SW30); the isolates could be strongly
inhibited by CXCR4 inhibitors but only modestly by CCR5 inhibitors
(Cilliers et al., 2003). These earlier results can now be explained by
the observation that although these isolates are dualtropic, they are
dominated by X4 variant clones.
An alternative explanation of our ﬁndings is that these isolates
changed their coreceptor preference during in vitro passages in PBMCco-cultures as has been previously described (Voronin et al., 2007).
This possible explanation is supported by the ﬁnding that isolates
CM9 and SW30 displayed remarkably lower CCR5 utilization capacity
(Table 1) than was previously described (Cilliers et al., 2003). It is also
worth noting that although isolates BW17, SW20 and Du36_5 showed
a possible bias towards CCR5 utilization and were clearly dualtropic,
all the envmolecular clones generated from these isolates by bulk PCR
ampliﬁcation were CXCR4-only using. This ﬁnding strongly suggested
that the bulk PCR could be biased towards X4 viruses. We therefore
performed limiting endpoint dilution PCR on one dualtropic viral
isolate (Du36_5) which was biased towards CCR5 utilization (Table
1). Remarkably, of 26 functional env clones generated by this
approach, 24 exhibited dualtropism, one used CXCR4 exclusively
and one used CCR5 exclusively. We therefore conclude that dualtropic
HIV-1 subtype C isolates are dominated by X4 and X4R5 clones with
negligible proportion of R5 monotropic clones.
It has been recently proposed that coreceptor switching is
associated with deleterious mutations in env that diminish CCR5-
tropism as mutations associated with CXCR4 utilization accumulate
(Coetzer et al., 2008). Although we did not directly test for coreceptor
binding in this study, our results are consistent with the proposal by
Coetzer et al. and with their observation that coreceptor switching is
associated with a rapid decrease in the ability to use CCR5. Our results
may suggest that in HIV-1 subtype C, the mutations required for
adaptation to CXCR4 utilization signiﬁcantly reduce the ability of env
to utilize CCR5, thus resulting in reduced ﬁtness of CCR5 utilizing
viruses. This could in turn lead to the selection and ampliﬁcation of
clones able to utilize CXCR4. We can speculate that given the low
frequency of HIV-1 subtype C CXCR4 utilizing viruses reported in
various studies, more accumulated mutations are required for
switching to CXCR4 utilization for this subtype. Alternatively, the
changes required for a switch to CXCR4 utilization may result in a
bigger ﬁtness deﬁcit for HIV-1 subtype C CCR5-tropic variants thus
leading to selection against these viruses once adaptation to CXCR4
utilization has been accomplished. Further studies will be required to
carefully investigate the speciﬁc localization and nature of comple-
mentary mutations required for HIV-1 subtype C env coreceptor
switch.
We also investigated the genetic characteristics associated with
CXCR4-usage or dualtropism for HIV-1 subtype C viruses. Our results
may be limited by founder effects since we could not generate R5
sequences from the study isolates but we nevertheless had HIV-1
subtype C R5 sequences available from the Los Alamos database that
facilitated this comparative analysis. As described for HIV-1 subtype B,
the subtype C third variable loop of gp120 (V3 region) is a major
determinant of whether CXCR4 or CCR5 will be the accessory protein
used by the virus for membrane fusion (Cilliers et al., 2003; Coetzer et
al., 2007; Coetzer et al., 2006; Fouchier et al., 1992; Morris et al., 2007;
Ndung'u et al., 2006). Typically, the V3 region consists of approxi-
mately 35 amino acids in CCR5-tropic viruses (Coetzer et al., 2006).
Consistent with earlier studies, we found that V3 loop amino acid
characteristics are important determinants of coreceptor tropism. In
most cases, we found that the V3 loop crown of CXCR4-utilizing
clones had basic amino acid substitutions which differed from the
canonical GPGQ sequence found in CCR5 HIV-1 subtype C viruses to
GPGX (where X is any other amino acid), GRGH, GPGR or GPRY. X4
variants are more variable than R5 viruses in the V3 region
particularly at positions 11 and 25 which tend to be mostly positively
charged amino acids, often arginine (R), lysine (K) or histidine (H).
We found the presence of a basic amino acid at both or one of these
positions for the majority of clones in this study (85%). In addition, in
X4 variants there may be insertions particularly between positions 13
and 14 of the V3 loop contributing to an increased length. We found
amino acid insertions in 71% of clones in this study. X4 variants may
also be distinguished from R5 viruses as they usually have an
increased net V3 charge. Consistent with these observations, we
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of +5 or more.
The V3 region however, is not the exclusive determinant of
coreceptor usage and other regions within the env gene may also
contribute to viral tropism. The V1/V2 and V4/V5 regions have been
implicated in playing a role in determining the biological phenotype
of the virus. Speciﬁcally, the number of N-linked carbohydrate
moieties in these variable loops has been associated with coreceptor
determination (Chohan et al., 2005; Coetzer et al., 2008; Masciotra et
al., 2002; Pollakis et al., 2001). Here we found a strong association
between the number of N-linked glycosylation sites and coreceptor
utilization with X4 clones having a signiﬁcantly higher number of
these sites than R5 clones from the database overall and in the V1/V2
or V4/V5 regions (Figs. 4A–C). In contrast in the V3 region, the number
of sites was signiﬁcantly higher in R5 sequences than X4/X4R5
sequences (Fig. 4D). A previous longitudinal study of HIV-1 env
evolution showed no signiﬁcant changes in N-linked glycosylation
sites of 23 viral isolates from 5 patients followed for 2–4 years
(Coetzer et al., 2007). Therefore our ﬁndings may suggest a rapid
accumulation of N-linked glycosylation sites as coreceptor tropism
switches, as opposed to a slow accumulation of these sites over time.
This is consistent with recent ﬁndings of rapid decline in CCR5
utilization as alternate coreceptor utilization emerges in HIV-1
subtype B infection (Coetzer et al., 2008). In both HIV-1 subtypes A
and C, shorter V1/V2 loop sequences and fewer predicted N-linked
glycosylation sites have been correlated with preferential heterosex-
ual viral transmission (Chohan et al., 2005; Derdeyn et al., 2004). We
did not ﬁnd signiﬁcant differences in V1/V2 length between R5 and X4
clones in this study but a trend towards shorter V4/V5 for X4 clones
was noted (Figs. 4E–F). Further longitudinal studies will be necessary
in order to better understand HIV-1 subtype C transmission,
coreceptor switching and the env genetic characteristics associated
with these processes. Overall, our results suggest that sequence
characteristics in the V3 loop, the V4/V5 loop length as well as the
number of env predicted N-linked glycosylation sites are the primary
genotypic determinants for viral tropism in HIV-1 subtype C.
It is worth noting that we did not perform limiting endpoint
dilution of samples in this study except for isolate Du36_5. Therefore
we cannot completely rule out the presence of substantial frequencies
of R5-monotropic viruses in the quasispecies of the isolates where
endpoint dilution was not used. However, the absence of these clones
in bulk ampliﬁed clones, in CCR5 only expressing cells and in endpoint
diluted Du36_5 isolate that is biased towards CCR5 is all suggestive of
absence of such quasispecies or presence at very low frequency. Our
results appear to contradict the recent ﬁndings of Irlbeck et al. (2008)
but it must be emphasized that in that study, samples were analyzed
directly from plasma in contrast to our study in whichwe examined in
vitro propagated isolates. Further studies will be needed to determine
whether env clones directly obtained from patients with dualtropic
HIV-1 subtype C viruses have a bias towards CCR5 or CXCR4 tropism.
In conclusion, we show in this study that dualtropic viral isolates
consist of predominantly X4 and X4R5 clones. Thirty of 35 env clones
analyzed from PBMCs utilized X4 only as the coreceptor for entry into
cells, whereas 5 of 35 clones tested displayed dualtropism and no
CCR5-only utilizing clones were identiﬁed. R5 monotropic clones
could not be detected even when the isolates were cultured in cells
expressing CCR5 coreceptor only. We also failed to detect a signiﬁcant
number of R5 monotropic clones when we changed our approach of
viral ampliﬁcation from bulk PCR to limiting endpoint dilution PCR for
one dualtropic isolate showing bias towards CCR5 tropism. Viral env
sequences from both CXCR4 and CCR5-expressing cells were
indistinguishable and possessed X4/dualtropic characteristics. Fur-
thermore, we describe env sequence characteristics associated with
CXCR4 utilization in HIV-1 subtype C. In addition to sequence changes
in the env V3 region, we identify the number of N-linked glycosylation
sites in the V1/V2, V3 and V4/V5 regions as major determinants ofcoreceptor utilization in HIV-1 subtype C. We also show that the
length of the V4/V5 is a possible determinant of coreceptor utilization.
We note that our results are consistent with recent ﬁndings of the
rapid loss of ﬁtness of CCR5 envelope as coreceptor switching emerges
and suggest that the sequence characteristics associated with
coreceptor switch must occur rapidly in vivo. Further studies are
needed to better characterize coreceptor switching, particularly in the
context of HIV-1 subtype C, the predominant subtype in the world.
We have generated 35 full-length CXCR4- or dualtropic clones of HIV-
1 subtype C, important reagents that will facilitate further functional
studies of this globally predominant subtype. Our results have
important implications for coreceptor antagonist design and applica-
tion, and further contribute to better understanding of HIV-1
pathogenesis.
Materials and methods
Viral isolates
Seven primary viral isolates were analyzed in this study. BW17 is a
dualtropic HIV-1C virus isolated in 1996 from an infected person with
acquired immunodeﬁciency syndrome (AIDS) in Botswana (Ndung'u
et al., 2006). TM1B; RP1; SW20; SW30; CM9 and Du36_5 were
obtained from the AIDS Virus Research Unit, National Institute for
Communicable Diseases, Johannesburg, South Africa and were from
patients at various disease stages: acute infection (Du36_5), slow
progressor (TM1B), rapid progressor (RP1) and AIDS (SW20; SW30;
CM9) (Choge et al., 2006; Cilliers et al., 2003; Coetzer et al., 2006).
Cells and cell lines
U87.CD4 cells with or without the expression of the chemokine
receptors CCR5 or CXCR4 were obtained from the NIH AIDS Research
and Reference Reagent Program (Rockville, MD). U87.CD4 cells
without chemokine receptors were cultured in Dulbecco's modiﬁed
eagles medium (DMEM) containing L-glutamine (Gibco, NY, USA)
supplemented with 15% heat inactivated fetal bovine serum (FBS)
(Gibco, NY, USA), 300 μg/ml G418 (Sigma, Germany) and 50 μg/ml
penicillin–streptomycin (Gibco, NY, USA). U87.CD4 cells expressing
CCR5 or CXCR4were propagated in the samemedium but additionally
supplemented with 1 μg/ml puromycin (Sigma, Germany). 0.5×106
cells were cultured in 6-well ﬂat-bottomed plates in a total of 2 ml
culture medium at 37 °C and 5% CO2.
293T cells were obtained from the NIH AIDS Research and
Reference Reagent Program (Rockville, MD) and were cultured in
DMEM containing L-glutamine supplemented with 10% heat inacti-
vated FBS and 50 μg/ml gentamicin (Sigma, Germany). 50,000 293T
cells per well were seeded in a total volume of 0.3 ml per well of a 48-
well ﬂat-bottomed plate. These cells were incubated at 37 °C in 5% CO2
overnight before transfection.
Viral isolates propagation and DNA extraction
PBMCs from anonymous low risk HIV-negative volunteers were
separated by density-gradient centrifugation on Ficoll-Paque (Amer-
sham Biosciences, Uppsala, Sweden). We conﬁrmed that the samples
were HIV-negative by performing HIV RNA testing on the plasma
(Ampliscreen v1.5, Roche Diagnostics, Rotkreuz, Switzerland). 5×106
PBMCs from 2 donors were combined and stimulated by culturing in
RPMI 1640 with penicillin–streptomycin (50 μg/ml and 50 U/ml), 10%
heat inactivated FBS, 5 μg/ml phytohaemagglutinin (PHA) (Sigma,
Germany) and 20 U/ml interleukin-2 (IL-2) (Roche Applied Science,
Germany) at 37 °C and 5% CO2 for 72 h in a T-25 ﬂask. For infection of
the stimulated PBMCs, 5 ng p24 antigen equivalent of virus was used.
On days 1, 4, 7, and 10, 50% of the media was removed and replaced
with fresh medium. Aliquoted supernatant was retained for
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supernatant was removed and preserved for p24 antigen quantiﬁca-
tion. Cells were harvested and resuspended in 200 μl PBS. DNA was
then extracted using the QiaAmp DNA Blood Mini kit (Qiagen,
Germany).
Conﬁrmation of dualtropism of primary viral isolates
PBMC-grown virus corresponding to 2 ng of p24 HIV-1 antigen
was used for infection of U87.CD4 cells expressing either CCR5 or
CXCR4. On days 0, 4, 7 and 10 half of the media was removed and
replaced with fresh medium. The removed supernatant was retained
for quantiﬁcation of p24 antigen using the Vironostika HIV-1 Antigen
Microelisa system (Biomerieux, Boxtel, Netherlands). Previously well-
characterized dualtropic (Du179) and CCR5-tropic (BWM01_5)
primary isolates were used as positive controls.
Ampliﬁcation of envelope (env) gene
The 3 kb env gene was ampliﬁed by polymerase chain reaction
(PCR) using Phusion Hot Start High-Fidelity DNA Polymerase
(Finnzymes, Finland) with the following primers: Env1Adir 5′-
CACCGGCTTAGGCATCTCCTATGGCAGGAAGAA-3′ and EnvM 5′-
TAGCCCTTCCAGTCCCCCCTTTTCTTTTA-3′. The forward primer Env1A-
dir was designed to include the 4 base pair sequence (CACC)
necessary for directional cloning on the 5′ end. Cycling conditions
were as follows: a 5 minute denaturation at 94 °C, followed by
35 cycles of 30 s at 94 °C, 30 s at 55 °C, and 4 min at 72 °C. The ﬁnal
extension was at 72 °C for 10 min . The ampliﬁed product was then
run on a 1% agarose gel and gel puriﬁed using the Qiaquick gel
extraction kit (Qiagen, Germany).
Cloning
Once the DNA was puriﬁed, the env of each primary viral isolate
was cloned into the pcDNA3.1D/V5-His-TOPO vector (Invitrogen,
Carlsbad, CA). For the transformation procedure, Stratagene XL-10
Gold Ultracompetent cells (Stratagene, USA) were used. Molecular
clones were screened as follows. A colony PCR was performed after
the colony was incubated for 1.5 h at 37 °C with continuous shaking
(225 rpm) in a 96-well plate containing 100 μl Luria Bertani (LB)
media (Sigma, Germany) and ampicillin (100 μg/ml) (Calibiochem,
Darmstadt, Germany) to determine positivity of the cloned insert. This
is a directional env insert-speciﬁc PCR as it uses the forward primer T7
(5′ TAATACGACTCACTATAGGG 3′) found on the vector and reverse
primer Env M which is env speciﬁc. SuperTherm Taq Polymerase
(Southern Cross Biotechnology, Cape Town, South Africa) was used
and cycling conditions were as follows: denaturation for 5 min at
94 °C, followed by 35 cycles of 30 s at 94 °C, 30 s at 55 °C, and 4 min at
68 °C. The ﬁnal extension was for 10 min at 68 °C. The ampliﬁed
products were then run on a 1% agarose gel. Clones were considered
positive if they yielded a 3 kb band on an agarose gel. These clones
were then grown up at 37 °C overnight with shaking in 3 ml LB broth
containing 100 μg/ml ampicillin. Plasmid DNAwas then isolated using
Qiaprep Spin Miniprep kit by following the manufacturer's instruc-
tions (Qiagen, Germany). The ﬁrst ﬁve functional env clones identiﬁed
from each isolate were selected for further analysis.
Limiting endpoint dilution PCR
A limiting endpoint dilution PCR was performed on one primary
viral isolate, Du36_5 in order to determine whether the bulk PCR
resampling bias resulted in clones biased towards either CCR5 or
CXCR4 coreceptor usage. Single genome ampliﬁcation was undertak-
en as previously described (Salazar-Gonzalez et al., 2008). Primers
and cycle conditions were the same as used in the bulk PCR reactions.Once conﬁrmed by agarose gel electrophoresis, 30 PCR products were
puriﬁed and cloned and coreceptor usage was tested for the 26 clones
that were functional.Coreceptor usage assays
Cotransfection was carried out by ﬁrst combining 50 μl serum
free DMEM and 2.5 μl Fugene reagent (Roche Applied Science,
Germany) and incubating for 5 min at room temperature. This was
then incubated at room temperature together with 0.6 μg gp160
env DNA (i.e. cloned product) and 0.3 μg pNL4-3.Luc.R-E- (Connor
et al., 1995; He et al., 1995). pNL4-3.Luc.R-E- is a full-length HIV
plasmid with two frameshifts that render the clone env and vpr
deleted. The reporter ﬁreﬂy luciferase gene has been inserted into
the nef gene. The transfection mixture was incubated for 30 min ,
and then added to assigned wells of the plate seeded with 293T and
incubated at 37 °C and 5% CO2 for 48 h . The supernatant together
with 7.5 μg/ml DEAE-Dextran (Sigma, Germany) was added to U87.
CD4 cells as well as U87.CD4 cells expressing the coreceptors CXCR4
or CCR5. This was incubated at 37 °C and 5% CO2 for 48 h . The cells
were lysed using Glo Lysis buffer (Promega, Madison, WI, USA) and
incubated with Bright-Glo Assay reagent (Promega, Madison, WI,
USA). The luciferase activity was then determined using the Turner-
Biosystems Modulus Microplate instrument (Promega, Madison, WI,
USA). A negative control consisting of the plasmid pNL4-3.Luc.R-E-
and various positive controls were used in each coreceptor
expressing cell line. The positive controls were previously charac-
terized env clones Du179 (dualtropic), 96BWM01_5 (R5), and
96BW17#10 (X4). In addition, for each assay plate, 100 nM of
CCR5 inhibitor RANTES and 500 nM of CXCR4 inhibitor AMD3100
were used with the respective controls to conﬁrm speciﬁcity of
entry into target cells. Experiments were done in duplicate and the
average relative luminescence units (RLUs) for each clone were
calculated. A positive result was considered to be twice the average
of the negative control plus standard deviation.Sequencing and sequence analysis
The env gene was sequenced after cloning using the ABI PRISM Big
Dye Terminator Cycle Sequencing Ready Reaction kit version 3.1
(Applied Biosystems, CA, USA). Sequences were assembled and edited
using Sequencher 4.8. They were then aligned with Mega 4.
Phylogenetic trees were constructed in Paup 4.0 to evaluate the
clustering of these sequences with each other and with subtype
references. Phylogenetic trees were then visualized using Treeview
1.6.6. The consensus sequence for clones from each isolate was
generated using BioEdit Sequence Alignment Editor Software (Tom
Hall, North Carolina State University). Coreceptor utilization was
predicted using the web-based subtype C-speciﬁc position-speciﬁc
scoring matrix (C-PSSM) programme (http://indra.mullins.microbiol.
washington.edu/pssm/), a bioinformatics tool that reliably predicts
coreceptor phenotype using V3 loop sequences (Jensen et al., 2006).
Predicted N-linked glycosylation sites were examined using the web-
based programme N-GLYCOSITE (www.hiv.lanl.gov). All reference
sequences were obtained from the Los Alamos database (www.hiv.
lanl.gov).Nucleotide sequence accession numbers
The sequence data obtained from this study have been submitted
to Genbank under the following accession numbers: FJ846629–
FJ846662 and selected clones will be deposited into the NIH AIDS
Research and Reference Reagent Program repository.
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